arecoline has been researched along with Age-Related Memory Disorders in 8 studies
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.
arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cerebral demyelination is possibly one of the main pathological factors involved in the development of schizophrenia." | 5.51 | Arecoline attenuates memory impairment and demyelination in a cuprizone-induced mouse model of schizophrenia. ( Adilijiang, A; He, J; Li, X; Lin, D; Wang, W; Xu, Z; You, P, 2019) |
| " No adverse drug effects occurred." | 2.67 | Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. ( Asthana, S; Berardi, A; Haxby, JV; Morris, PP; Raffaele, KC; Soncrant, TT, 1993) |
| "Cerebral demyelination is possibly one of the main pathological factors involved in the development of schizophrenia." | 1.51 | Arecoline attenuates memory impairment and demyelination in a cuprizone-induced mouse model of schizophrenia. ( Adilijiang, A; He, J; Li, X; Lin, D; Wang, W; Xu, Z; You, P, 2019) |
| "The discovery of cholinergic deficit in Alzheimer's disease (AD) patient's brain has triggered research efforts, using cholinomimetic approaches for their efficacy in AD therapy." | 1.35 | Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models. ( Chandra, JN; Malviya, M; Rangappa, KS; Sadashiva, CT; Subhash, MN, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumar, YC | 2 |
| Malviya, M | 3 |
| Chandra, JN | 2 |
| Sadashiva, CT | 2 |
| Kumar, CS | 1 |
| Prasad, SB | 1 |
| Prasanna, DS | 1 |
| Subhash, MN | 3 |
| Rangappa, KS | 3 |
| Mythri, RB | 1 |
| Venkateshappa, C | 1 |
| Xu, Z | 1 |
| Adilijiang, A | 1 |
| Wang, W | 1 |
| You, P | 1 |
| Lin, D | 1 |
| Li, X | 1 |
| He, J | 1 |
| Brinkman, SD | 1 |
| Gershon, S | 1 |
| Soncrant, TT | 1 |
| Raffaele, KC | 1 |
| Asthana, S | 1 |
| Berardi, A | 1 |
| Morris, PP | 1 |
| Haxby, JV | 1 |
| Leanza, G | 1 |
| Muir, J | 1 |
| Nilsson, OG | 1 |
| Wiley, RG | 1 |
| Dunnett, SB | 1 |
| Bjorklund, A | 1 |
| Hironaka, N | 1 |
| Ando, K | 1 |
1 review available for arecoline and Age-Related Memory Disorders
| Article | Year |
|---|---|
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans | 1983 |
2 trials available for arecoline and Age-Related Memory Disorders
| Article | Year |
|---|---|
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans | 1983 |
Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Body Temperature; Cognition; Dose-Response Re | 1993 |
6 other studies available for arecoline and Age-Related Memory Disorders
| Article | Year |
|---|---|
Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models.
Topics: Alzheimer Disease; Animals; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship | 2008 |
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arecoline; Cerebral Cortex; Dose-Respons | 2009 |
Arecoline attenuates memory impairment and demyelination in a cuprizone-induced mouse model of schizophrenia.
Topics: Animals; Arecoline; Chelating Agents; Cholinergic Agonists; Cuprizone; Demyelinating Diseases; Disea | 2019 |
Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Topics: Acetylcholine; Alzheimer Disease; Animals; Arecoline; Binding, Competitive; Brain; Disease Models, A | 2008 |
Selective immunolesioning of the basal forebrain cholinergic system disrupts short-term memory in rats.
Topics: Animals; Antibodies, Monoclonal; Arecoline; Cholinergic Agents; Conditioning, Operant; Female; Hippo | 1996 |
Effects of cholinergic drugs on scopolamine-induced memory impairment in rhesus monkeys.
Topics: Animals; Arecoline; Cholinesterase Inhibitors; Macaca mulatta; Male; Memory; Memory Disorders; Musca | 1996 |